Discovered by BIOTEC research team together with the Medicines for Malaria Venture (MMV), the patented P218 compound was designed based-on 3-dimensional structures of malaria protein target, dihydrofolate reductase, in order to circumvent mutations that had led to resistance to pyrimethamine, […]
Recent Posts
- BIOTEC’s researchers have received funding from BactiVac, the Bacterial Vaccines Network to develop a Novel Vaccine Approach to Reduce Antibiotic Dependence in Aquaculture
12/11/2025 - BIOTEC Collaborates with FAO and UN Agencies at BIIF 2025 and Hosts Delegations to Explore Future Collaboration
12/04/2025 - ASEANSafe2025: Safer Food in a Climate Challenging Era
11/25/2025